Advancements in Nanomedicine for the Diagnosis and Treatment of Kidney Stones

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 1401 - 1423

Published: Feb. 1, 2025

Abstract: Kidney stones constitute a common condition impacting the urinary system. In clinical diagnosis and management, traditional surgical interventions pharmacological treatments are primarily utilized; however, these methods possess inherent limitations. Presently, field of nanomedicine is undergoing significant advancements. The application nanomaterials in biosensors enables accurate assessment ion composition. Furthermore, contrast agents developed from materials can improve signal-to-noise ratio enhance image clarity. By mitigating oxidative stress-induced cellular damage, inhibit formation kidney efficacy drug delivery as effective carriers. Additionally, by modifying physical chemical properties bacteria, effectively eliminate bacterial presence, thereby preventing severe complications. This review explores advancements technology related to early detection risk factors, diagnosis, treatment their associated Keywords: nanomaterials, stones, stress, biomaterial

Language: Английский

---

Enhancement of the in vitro anti-leukemic effect of the histone deacetylase inhibitor Romidepsin using Poly-(D,L-lactide-co-glycolide) nanoparticles as a drug carrier

European Journal of Pharmaceutical Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 107043 - 107043

Published: Feb. 1, 2025

Language: Английский

---

Nanotechnology-based drug delivery for breast cancer treatment: Current applications and future directions

European Journal of Medicinal Chemistry Reports, Journal Year: 2025, Volume and Issue: unknown, P. 100268 - 100268

Published: April 1, 2025

Language: Английский

---

Production of Hydrophobic Microparticles at Safe-To-Inject Sizes for Intravascular Administration

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(1), P. 64 - 64

Published: Jan. 6, 2025

Background/Objectives: Hydrophobic microparticles are one of the most versatile structures in drug delivery and tissue engineering. These constructs offer a protective environment for hydrophobic or water-sensitive compounds (e.g., drugs, peroxides), providing an optimal solution numerous biomedical purposes, such as oxygen therapeutics. The intravascular administration requires safe-to-flow particle profile, which typically corresponds to maximum size 5 µm-the generally accepted diameter thinnest blood vessels humans. However, production below this range remains largely unexplored. In work, we investigate fabrication at safe-to-inject sizes (<5 µm) administration. Methods: Polycaprolactone (PCL MPs) produced using double-emulsification method with tip ultrasonication, various parameters molecular weight, PCL concentration, type stabilizer, filtration) optimized obtain particles µm. Results: We achieve MP distribution 99.8% limit, prove that these can flow without obstruction through microfluidic model emulating thin human capillary (4.1 µm × 3.0 width heigh). Conclusions: Overall, demonstrate be fabricated simple scalable setup, paving way towards their applicability new injectables.

Language: Английский

---

Advances of nanomedicine targeting the interface of cholesterol metabolism and immune evasion

Chinese Chemical Letters, Journal Year: 2025, Volume and Issue: unknown, P. 110921 - 110921

Published: Feb. 1, 2025

Language: Английский

---

Sustained Delivery of Liraglutide Using Multivesicular Liposome Based on Mixed Phospholipids

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 203 - 203

Published: Feb. 6, 2025

Background: Although peptides are widely used in the clinical treatment of various diseases due to their strong biological activity, they usually require frequent injections owing poor vivo half-life. Therefore, there is a need for sustained peptide formulations. Methods: In this study, liraglutide (Lir) and biocompatible multivesicular liposomes (MVLs) were utilized as model drug sustained-release carriers, respectively. The release rate Lir-MVLs was controlled by changing ratio SPC DEPC with different phase transition temperatures (PTT, PTTSPC = −20 °C, PTTDEPC 13 °C). Results: As increased, had more flexible lipid membranes, poorer structural stabilization, fewer internal vesicles larger particle sizes, contributing faster Lir. After subcutaneous injection Lir-MVLs, blood glucose concentration (BGC) db/db mice decreased levels. When SPC-DEPC greater than 85:15, too fast; BGC remained below 16 mM only 2–4 days, while when slow, case less 50:50, also 2–3 days. However, 75:25, could be maintained 8 indicating that properties best met pharmacological requirements Conclusions: This study investigated effects phospholipids PTT on characteristics provided ideas design preparations.

Language: Английский

---

Local delivery of ibrutinib by folate receptor-mediated targeting PLGA-PEG nanoparticles to glioblastoma multiform: in vitro and in vivo studies

Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 16

Published: Feb. 17, 2025

Glioblastoma multiforme (GBM) is a widespread and life-threatening kind of brain cancer, which has high mortality rate. Ibrutinib, Bruton's tyrosine kinase (BTK) inhibitor, irreversibly adheres to conserved cysteine residue two enzymes BTK BMX, inhibiting their activities leads suppression the growth glioma cells. This study synthesized PLGA-PEG-folate (PPF) polymer subsequently encapsulated ibrutinib within PPF nanoparticles (IBT-PPF-NPs). HNMR spectra confirmed synthesis polymer. The efficiency IBT-PPF-NPs was 97 ± 2.26% with 8.8 0.2% drug loading. particle size 208 4.8nm. IC50 value free ibrutinib, IB-PPF-NPs, in PLGA NPs (IB-P-NPs) 10.2, 7.6, 10.13 µM C6 cell lines, whereas U-87 MG cells 24.4, 16, 25.2 respectively. cellular uptake FITC-PPF-NPs increased from 47.6% 90.3% 55% 97.3% compared FITC-P-NPs. vivo results indicate significant reduction tumor treatment groups comparison control groups, while group that received intratumoral injection IB-PPF-NPs exhibited greater reduction. folate-targeting agent enhances nanoparticles' effectiveness by promoting through endocytosis pathway.

Language: Английский

---

Long-term controlled release with reduced initial burst release utilizing calcium ion-triggering nanoaggregates of pasireotide-loaded fattigated albumin nanoparticles

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125401 - 125401

Published: Feb. 1, 2025

Language: Английский

---

β2GPI-targeted polymeric nanoparticles form a protective layer to prevent vascular thrombosis in an anti-phospholipid syndrome model

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 27, 2025

Anti-phospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombotic vascular occlusion and maternal morbidity. Anti-coagulants remain pivotal drugs for the management of APS, but significant proportion patients do not benefit from long-term anti-coagulation may require an alternative therapy to prevent antibody deposition thrombosis. We have developed therapeutic approach based on use safe polymeric nanoparticles that selectively target beta2-glycoprotein I (β2GPI) deposited endothelial cells (tNPs). Their efficacy was tested in rat model APS infusing patients' sera containing medium-high titer antibodies against domain β2GPI. The tNPs bearing CH2-deleted anti-β2GPI recombinant as targeting agent recognize β2GPI failed induce blood clot formation. infused into rats immediately before competed with antibodies, preventing their binding and, consequence, resulted thrombus formations mesenteric vessels. Similar results were obtained injecting 24 hours administration Our findings suggest β2GPI-targeted represent stable formation vessel be used control thrombosis developing result acute triggering events.

Language: Английский

---

Delivery of Polypeptide Drugs Using Nanoparticles Made of Recombinant Spider Silks Derived From MaSp4 Protein

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 2609 - 2622

Published: March 1, 2025

Spider silk protein is a biocompatible and biodegradable that can self-assemble into various morphological materials for biomedical applications including drug delivery carriers. Spiders spin up to seven types of fibers, each containing multiple proteins. Despite the numerous potential these proteins, comprehensive in-depth research on their specific roles efficacy in has yet be conducted. The authors designed three new bioengineered spider proteins (M4R2, M4R4, M4R6) examined its property as carrier polypeptided drugs. To obtain M4R2, M4R6 constructs comprising 2, 4, 6 repeat units Araneus ventricosus major ampullate spidroin 4 (MaSp4) were engineered prokaryotic expression using Escherichia coli system. particles made silks produced high concentration potassium phosphate buffer. physical properties characterized by scanning electron microscopy (SEM) zeta analysis. cytotoxicity was analyzed MTT assay. loading release profiles drugs spectrophotometrically. M4R6, constructed, produced, purified. These exhibit self-assembly formed particles. Furthermore, not cytotoxic had similar particle sizes but differed efficiency rate. M4R2 more efficient (>95%) than M4R4 In addition, continuous ChMAP-28 from over 30 days indicates sustained-release positively charged peptide stability, excellent efficiency, performance make them an ideal choice We developed recombinant demonstrating particles, with stable colloidal properties, drugs, controlled rates, are promising particulate systems

Language: Английский

---